Unknown

Dataset Information

0

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma.

ABSTRACT:

SUBMITTER: Duhrsen U 

PROVIDER: S-EPMC8129096 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
| S-EPMC3918114 | biostudies-literature
Unknown A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
| S-EPMC8253277 | biostudies-literature
Unknown Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
| S-EPMC4283736 | biostudies-literature
Unknown Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
| S-EPMC8711638 | biostudies-literature
Unknown Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis.
| S-EPMC8674688 | biostudies-literature
Unknown AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
| S-EPMC7035866 | biostudies-literature
Unknown Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
| S-EPMC7032881 | biostudies-literature
Unknown Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
| S-EPMC7698117 | biostudies-literature
Unknown Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report.
| S-EPMC4191682 | biostudies-literature
Unknown Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
| S-EPMC8363059 | biostudies-literature